Notice of Annual General Meeting of Shareholders
13 Maggio 2021 - 5:45PM
Notice of Annual General Meeting of Shareholders
Amsterdam, The Netherlands, 13 May
2021 – Kiadis Pharma
N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam
and Brussels: KDS), a clinical-stage biopharmaceutical
company, today announces that its Annual General Meeting of
shareholders ("AGM”) will be held at 15:00 CEST on
28 June 2021.
Pursuant to temporary emergency legislation
regarding COVID-19 in The Netherlands, the AGM can only be accessed
electronically. This means that it will not be possible to attend
the AGM in person. Instead, the Company will provide instructions
how to connect to the virtual AGM (audio only) to those
shareholders that have registered on time for the AGM. Although
this will not be interactive, shareholders who have registered will
be able to submit written questions, to grant a proxy and issue
voting instructions before the AGM.
The notice, agenda and proxy form for the AGM
are available on the Investors’ section of the Kiadis Pharma
website at:
http://www.kiadis.com/investors/shareholders-meetings/.
Dutch Translation/Nederlandse
vertaling
Amsterdam, Nederland, 13 mei 2021
- Kiadis Pharma N.V. (“Kiadis Pharma” of
de
“Vennootschap”)
(Euronext Amsterdam en
Brussel: KDS), een biofarmaceutisch bedrijf in
klinische fase, kondigt vandaag aan dat de jaarlijkse Algemene
Vergadering van Aandeelhouders
(“AVA”) wordt gehouden op 28 juni
2021 om 15:00 uur CEST.
Conform de tijdelijke noodwetgeving met
betrekking tot COVID-19 in Nederland is de AVA alleen elektronisch
toegankelijk. Dit betekent dat het niet mogelijk zal zijn om de AVA
in persoon bij te wonen. In plaats daarvan zal de Vennootschap de
aandeelhouders die zich op tijd voor de AVA hebben aangemeld,
instructies geven over hoe zij verbinding kunnen maken met de
virtuele AVA (alleen audio). Hoewel dit niet interactief zal zijn,
zullen de aldus aangemelde aandeelhouders vóór de AVA schriftelijke
vragen kunnen stellen en een volmacht en steminstructies kunnen
geven.
De aankondiging, agenda voor de AVA en het
volmacht formulier zijn beschikbaar op de Investors sectie de
Kiadis Pharma website op:
http://www.kiadis.com/investors/shareholders-meetings/.
De bovenstaande tekst is een vertaling
van de Engelstalige oproeping voor de AVA. Bij eventuele
verschillen is de tekst van de Engelstalige oproeping
altijd leidend.
About Kiadis Founded in 1997,
Kiadis is committed to developing innovative cell-based medicines
for patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life. Following a successful public
offer, Sanofi and Kiadis have now joined forces to expand and
accelerate the potential benefits of novel cell-based therapies to
treat cancer patients.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com. As announced by
Kiadis on 26 April 2021
(https://ir.kiadis.com/news-releases/news-release-details/delisting-kiadis-will-be-effective-25-may-2021),
the delisting of the Company’s shares from Euronext Amsterdam and
Euronext Brussels will be effective as of 25 May 2021.
For more information:
KiadisMaryann
Cimino, Director Investor Relations& Corporate AffairsTel: +1
617 710-7305m.cimino@kiadis.com |
Kiadis Media Relations
ContactsLifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 6 538 16
427lmelens@lifespring.nlOptimum Strategic
Communications:Mary Clark, Supriya MathurTel: +44 203 950
9144kiadis@optimumcomms.com |
|
|
Kiadis Forward-Looking Statement
Certain statements, beliefs and opinions in this press release
are forward-looking, which reflect Kiadis’ or, as appropriate,
Kiadis’ officers’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of known and unknown risks, uncertainties and assumptions
that could cause actual results, performance, achievements or
events to differ materially from those expressed, anticipated or
implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, regulation, competition and technology, can cause actual
events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis expressly disclaims any obligation or
undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.